{"id":7806,"date":"2026-02-24T06:08:29","date_gmt":"2026-02-24T06:08:29","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/nad-plus\/"},"modified":"2026-04-09T14:26:15","modified_gmt":"2026-04-09T21:26:15","slug":"nad","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/nad\/","title":{"rendered":"NAD+ \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to NAD+ product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on NAD+ \u2014 for educational purposes only<\/p>\n

\nNAD+ Biosynthesis Pathways<\/summary>\n
\n

NAD+ is synthesized through three main pathways: (1) de novo synthesis from tryptophan via the kynurenine pathway, (2) the Preiss-Handler pathway from nicotinic acid (niacin), and (3) the salvage pathway from nicotinamide (NAM) via nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can also be converted to NAD+ through salvage pathway enzymes. NAMPT expression varies by tissue and decreases with age in some tissue models.<\/p>\n

Verdin E. “NAD+ in aging, metabolism, and neurodegeneration.” Science.<\/em> 2015. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nNAD+ as Sirtuin Substrate<\/summary>\n
\n

Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases that use NAD+ as a co-substrate, cleaving it to produce nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 deacetylates targets including PGC-1\u03b1, FOXO transcription factors, and p53. SIRT3, localized to mitochondria, deacetylates metabolic enzymes involved in fatty acid oxidation and the TCA cycle. Sirtuin activity is limited by intracellular NAD+ availability, creating a link between cellular NAD+ levels and sirtuin-mediated metabolic regulation.<\/p>\n

Imai S, Guarente L. “NAD+ and sirtuins in aging and disease.” Trends Cell Biol.<\/em> 2014. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nNAD+ Depletion by PARPs and CD38<\/summary>\n
\n

NAD+ is consumed by poly(ADP-ribose) polymerases (PARPs), which use NAD+ for ADP-ribosylation during DNA repair. PARP1 is the major NAD+ consumer during genotoxic stress, and excessive PARP activation can deplete cellular NAD+ pools. CD38, an ectoenzyme, is another major NAD+ consumer that increases with age in some tissues. CD38 catalyzes the hydrolysis of NAD+ to nicotinamide and ADP-ribose (or cyclic ADP-ribose). Research has characterized the competition between sirtuins, PARPs, and CD38 for the cellular NAD+ pool.<\/p>\n

Camacho-Pereira J et al. “CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism.” Cell Metab.<\/em> 2016. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nNAD+ Precursor Supplementation in Human Studies<\/summary>\n
\n

Clinical studies have examined oral supplementation with NAD+ precursors (NR and NMN) and measured changes in blood NAD+ levels. A systematic review of human trials found that NR supplementation increased whole blood NAD+ by 40\u2013142% depending on duration. NMN studies have similarly shown increases in blood NAD+ metabolites. These studies characterized pharmacokinetics, tolerability, and safety profiles, establishing that oral precursors can elevate circulating NAD+ levels in humans.<\/p>\n

Reiten OK et al. “Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing.” Mech Ageing Dev.<\/em> 2021. PMC<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to NAD+ product page Research Library Published research on NAD+ \u2014 for educational purposes only NAD+ Biosynthesis Pathways NAD+ is synthesized through three main pathways: (1) de novo synthesis from tryptophan via the kynurenine pathway, (2) the Preiss-Handler pathway from nicotinic acid (niacin), and (3) the salvage pathway from nicotinamide (NAM) via nicotinamide […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7806","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7806"}],"version-history":[{"count":1,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7806\/revisions"}],"predecessor-version":[{"id":8637,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7806\/revisions\/8637"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}